Organ Transplant Immunosuppressant Drugs Market

Global Organ Transplant Immunosuppressant Drugs Market: Key Trends  

Organ transplantation is slowly emerging as an effective method for the treatment of end-stage organ failure. Due to the increasing incidence of chronic ailments, the demand for organ replacement has risen considerably around the world. This subsequently fuels demand for advanced immunosuppressant drugs to prevent organ rejection post transplantation.

Despite recent advances in medical science, post-operative complications are still a major challenge that the global organ replacement immunosuppressant drugs market needs to address. The long-standing inadequate medical coverage for immunosuppressant drugs can compromise the quality of care offered to patients suffering from organ failure. According to Transparency Market Research (TMR), this factor will translate into negative growth for the global organ transplant immunosuppressant drugs market from 2015 to 2023.

Besides this, the high cost of organ transplantation and the advent of stem cell therapies are limiting the market’s trajectory. The global organ transplant immunosuppressant market stood at US$5.1 bn in 2014. Exhibiting a CAGR of -5.0% between 2015 and 2023, the market’s valuation is expected to reach US$3.2 bn by the end of 2023.

Use of Immunosuppressant Drugs during Kidney Transplantation to Significantly Increase

Based on transplant, the demand for immunosuppressant drugs used during kidney transplantation was the highest in 2014. In the last couple of years, kidney transplantation has emerged as the most preferred treatment method for end-stage renal diseases. It has proven more cost-effective than prolonged periods of dialysis. Hence, TMR projects the demand for kidney replacement procedures to rise at a considerable pace during the forecast period. This will in turn will boost demand for immunosuppressant drugs from the segment, which held over 53.4% of the market in 2014. The kidney transplant segment is expected to maintain its dominance in the market through the forecast period.

Furthermore, the market is expected to witness demand from the bone marrow transplant segment as novel immunosuppressant drugs are developed for the treatment of graft-versus-host diseases. The use of these drugs is also expected to increase during liver, heart, and lung transplants.

Robust Healthcare Infrastructure Fuels Demand for Immunosuppressant Drugs from North America

Regionally, North America led the global organ immunosuppressant drugs market with a share of 46.2% in 2014. The region exhibits high demand for immunosuppressant drugs due to the higher number of organ transplantations conducted therein. According to TMR, North America is expected to report the fastest growth due to the increasing number of successful organ replacement surgeries conducted in the region. This will in turn bolster demand for advanced immunosuppressant therapeutics.  

Europe emerged as the second largest market for immunosuppressant drugs in the same year. These two regions will continue to lead the global market due to the recent improvements in surgical techniques, technology, and immunosuppressant drug discovery. The robust healthcare infrastructure in North America and Europe will seal the dominance of these regions in the global market.

Novartis AG, Astellas Pharma, Inc., F. Hoffmann-La Roche Ltd., Pfizer, Inc., and Sanofi are some of the most prominent companies operating in the market.

Advances in Organ Transplant Immunosuppressant Drugs Market to Improve Solid Organ Transplantation

Immunosuppressants are crucial in organ transplantation primarily for two reasons: decreasing the risks of over immunosuppression and preventing graft rejection in patients. The former leads to infections and cancer. The need for improving the quality of life in organ recipients is the key underpinning. The growing demand for these in solid organ transplantation patients is boosting research and development activities in the organ transplant immunosuppressant drugs market. New approaches for changing signalling pathways have come to the fore for surgeons on the back of increased understanding of human immune system in recent decades. Particularly the effect of antibody therapies on signalling pathways notably pathways mediated by T cells and B cells is key to demand in the market. The use of antibody therapies as immunosuppressants in improving graft survival in solid organ and hematopoietic stem cell transplantation (SOT) is boosting the market prospects. Currently, SOT is one the only definitive therapies for various end-stage diseases in adults and of the liver and heart. Over recent years, lung transplantation has proved to be a lucrative avenue for companies pioneers in the organ transplant immunosuppressant drugs market. The growing morbidity and mortality of end-stage kidney diseases is one of the key trends bolstering the demand potential for immunosuppressants.

The COVID-19 pandemic is perhaps is one the worst health pandemics in history as evident in the several outbreaks with large economic, political, and social repercussions around the world, especially in 2020. The infections led to surge in mortality risks in patients who needed transplants. Since COVID-19 patients with acute infection had to undergo chronic immunosuppressive treatment, solid organ transplantation (SOT) was discouraged due to the increased risks. In particular, this derailed some transplant programs such as kidney transplants while presenting COVID patients with less options. The complexities in organ transplant transplantation posed some unsurmountable challenges for healthcare providers in the ecosystem of the organ transplant immunosuppressant drugs market. Nonetheless, significant progress has been made on the back of AI and other novel technologies to identify the right donors and recipients.